Dayli Partners

Medipixel, Inc. is a South Korean MedTech startup founded in 2017, specializing in artificial intelligence-based diagnostic software and semi-autonomous robotic systems for lung cancer and cardiac interventions. The company is comprised of a team of AI experts in computer vision, deep learning, and reinforcement learning, collaborating with top healthcare professionals, including those at Seoul Asan Medical Center, to enhance disease diagnosis and surgical procedures. Medipixel offers three primary solutions for intervention surgeons: an AI-based diagnosis tool that assists in identifying lesions during coronary angiography, a guide and planning solution that visualizes coronary arteries to facilitate guidewire manipulation, and an automated navigation engine that directs robotic units through arteries with real-time commands. These innovations aim to improve surgical outcomes and patient safety by reducing reliance on contrast agents and enhancing the precision of interventions.

Founded in 2017, CURAUM specializes in developing and selling oral care and sleep-related healthcare products. Its key offerings include Clium Cleaner for dental device cleaning, Clium S-Guard for managing obstructive sleep apnea and snoring, and the Clium System for personalized chronic sleeping disorder management.

Y-Biologics Inc. is a biotechnology company based in Daejeon, South Korea, specializing in the discovery and development of novel antibody therapeutics, particularly in the field of immuno-oncology. Established in 2007, the company has developed a bispecific antibody platform technology known as AliCE, which maintains the structural integrity of the parental antibody, ensuring high binding affinity to cancer antigens. Additionally, Y-Biologics has created the Y-max ABL, a unique library of human antibodies, which supports its research and development efforts. The company is recognized for its contributions to the global immuno-chemotherapeutic drug market and also offers contract research services, aiming to advance its position within the biotechnology sector.

Ubix Therapeutics, Inc. is a research and development company based in Seoul, South Korea, focused on the development of anti-cancer drugs utilizing a proprietary proteolysis targeting chimera platform. The company employs advanced inhibitor technology that degrades specific target proteins within cells, aiming to enhance therapeutic efficacy for various cancers. By binding to proteins associated with disease, Ubix Therapeutics seeks to provide life-saving medications for patients, thereby supporting both patients and medical professionals in the fight against cancer.

Tomocube designs and manufactures 3D optical microscopes that use holotomography to capture non-invasive, dye-free, real-time images of living cells and tissues. Its product line includes HT-1, HT-2, and HT-X1 models, along with software such as TomoAnalysis. The technology enables researchers in cell biology, regenerative medicine, immunology, and 3D biology to study dynamic cellular processes without sample preparation. Founded in 2015 and headquartered in Daejeon, South Korea, Tomocube serves the life science research and diagnostic markets.

GI Innovation, based in South Korea, specializes in bio-ventures by integrating basic science with translational innovation to develop biologics for global patients. Its strategic focus lies in immuno-oncology and inflammation/immunology diseases, leveraging the GI-SMART platform technology to efficiently optimize multi-targeting fusion protein therapeutics.

Master Meditech Inc. is a biotechnology company based in Seoul, South Korea, specializing in the development of new pharmaceuticals through protein structure identification and medicinal chemistry. Established in 2019, the company focuses on leveraging advanced scientific techniques to discover innovative drug candidates, aiming to address various medical needs. With a commitment to enhancing therapeutic options, Master Meditech is positioned at the intersection of technology and healthcare, striving to contribute to advancements in the pharmaceutical industry.

Novelty Nobility is a biotechnology company specializing in the research and development of antibody-based therapeutics targeting novel angiogenesis factors. The company focuses on ophthalmology and oncology, aiming to address unmet medical needs through innovative treatments.

Founded in 2017, CURAUM specializes in developing and selling oral care and sleep-related healthcare products. Its key offerings include Clium Cleaner for dental device cleaning, Clium S-Guard for managing obstructive sleep apnea and snoring, and the Clium System for personalized chronic sleeping disorder management.

CSK Inc. is a manufacturer specializing in products for the semiconductor and LCD industries, with operations in Asia, America, and globally. Founded in 1997 and headquartered in Yongin, South Korea, the company develops a range of solutions including plasma and wet scrubbers, thermal and wet scrubbers, and burn and wet combination scrubbers designed to purify harmful gases generated during semiconductor manufacturing. Additionally, CSK provides precursor delivery systems aimed at waste gas abatement. The company also serves the South Korean markets for display, solar, and LED technologies, positioning itself as a key supplier of exhaust management systems. As of August 2016, CSK operates as a subsidiary of Atlas Copco AB.

Sugentech Incorporated is an in-vitro diagnostic company based in Daejeon, South Korea, specializing in personal point-of-care testing products and personalized diagnosis solutions. Founded in 2011, the company focuses on developing innovative healthcare technologies by integrating biotechnology, information technology, and nanotechnology. Sugentech's product offerings include laboratory tests such as immunoblot processors and molecular diagnostics systems, as well as self-diagnostic home testing kits. Their portfolio features tests for various analytes, including C-reactive protein, procalcitonin, and troponin I, along with personal care tests like digital ovulation and pregnancy tests. Formerly known as Accugen Healthcare, Sugentech changed its name in 2013 to reflect its commitment to pioneering advancements in health diagnostics.

Medipixel, Inc. is a South Korean MedTech startup founded in 2017, specializing in artificial intelligence-based diagnostic software and semi-autonomous robotic systems for lung cancer and cardiac interventions. The company is comprised of a team of AI experts in computer vision, deep learning, and reinforcement learning, collaborating with top healthcare professionals, including those at Seoul Asan Medical Center, to enhance disease diagnosis and surgical procedures. Medipixel offers three primary solutions for intervention surgeons: an AI-based diagnosis tool that assists in identifying lesions during coronary angiography, a guide and planning solution that visualizes coronary arteries to facilitate guidewire manipulation, and an automated navigation engine that directs robotic units through arteries with real-time commands. These innovations aim to improve surgical outcomes and patient safety by reducing reliance on contrast agents and enhancing the precision of interventions.

MDimune Inc. is a South Korean therapeutics company focused on developing innovative drug delivery systems. Founded in 2015 and based in Seoul, the company specializes in the creation of cancer therapeutics using immune cell-derived and stem cell-derived vesicles. Its research and development efforts encompass a range of therapeutic areas, including personalized cancer treatments, osteoarthritis, chronic obstructive pulmonary disease, and neurodegenerative disorders. MDimune's proprietary platform enables targeted delivery of drugs, allowing for the development of novel therapeutics that enhance treatment efficacy. The company provides its vesicle-based delivery solutions to biotech and pharmaceutical enterprises, thereby facilitating advanced therapeutic options for patients.

Founded in 2014, HUINNO is a digital health company headquartered in Boston with offices in New York and Seoul. It develops healthcare devices to monitor vital signs such as blood pressure, heart rate, ECG, and SpO2, offering real-time data analysis via its app and cloud-based ecosystem. The company focuses on improving chronic cardiac disease management through wearable technology and AI-driven analytics.

Jeisys Medical, established in 2001 and headquartered in Seoul, South Korea, specializes in designing, developing, and manufacturing medical devices for various healthcare professionals, including plastic surgeons, dermatologists, and physicians. The company's portfolio spans across multiple treatment areas such as fat reduction, skin tightening, rejuvenation, and removal of unwanted pigments, tattoos, and acne. Notable products include LIPOcel, ULTRAcel Q+, and AcGen, marketed under brands like LIPOcel, ULTRAcel, and AcGen. Jeisys Medical distributes its products globally through a network of distributors.

Tomocube designs and manufactures 3D optical microscopes that use holotomography to capture non-invasive, dye-free, real-time images of living cells and tissues. Its product line includes HT-1, HT-2, and HT-X1 models, along with software such as TomoAnalysis. The technology enables researchers in cell biology, regenerative medicine, immunology, and 3D biology to study dynamic cellular processes without sample preparation. Founded in 2015 and headquartered in Daejeon, South Korea, Tomocube serves the life science research and diagnostic markets.

SCM Lifescience, founded in 2014, focuses on the research and development of innovative treatment options for challenging diseases. The company utilizes proprietary technologies for stem cell isolation and production, aiming to create new therapies that offer hope to patients and contribute to overall human welfare. Based in South Korea, SCM Lifescience is also involved in developing medicinal products and hair care solutions, leveraging its expertise in stem cell applications to address various health-related needs.

Y-Biologics Inc. is a biotechnology company based in Daejeon, South Korea, specializing in the discovery and development of novel antibody therapeutics, particularly in the field of immuno-oncology. Established in 2007, the company has developed a bispecific antibody platform technology known as AliCE, which maintains the structural integrity of the parental antibody, ensuring high binding affinity to cancer antigens. Additionally, Y-Biologics has created the Y-max ABL, a unique library of human antibodies, which supports its research and development efforts. The company is recognized for its contributions to the global immuno-chemotherapeutic drug market and also offers contract research services, aiming to advance its position within the biotechnology sector.

3D MediVision develops, manufactures, and sells 3D visualization and live-casting systems for surgery. Its product line includes 3D and 2D cameras, recorders, monitors, and ultrasound systems, and it offers SURGFLIX, a surgical content-sharing platform, and VeterFlix, a veterinary training platform. The imaging system can be mounted on surgical microscopes to convert the ocular view into a digital, multi-dimensional image that can be streamed or recorded for educational use. The company distributes its products through authorized distributors in India, Spain, Mexico, and China. Founded in 2011, it is based in Seoul, South Korea.

Ensol Biosciences Inc. is a biopharmaceutical company based in Daejeon, South Korea, specializing in the development of innovative therapies for serious conditions with limited treatment options, including degenerative disc disease, osteoarthritis, various cancers, Alzheimer's dementia, and type 1 diabetes. The company's drug pipeline features several candidates in clinical trials, such as Peniel 2000 for degenerative disc disease and Engedi 1000 for osteoarthritis. Additionally, it is advancing treatments like Charis 1000 for triple negative breast cancer and Moriah 1000 for Alzheimer's disease. Ensol Biosciences also provides contract drug development services, encompassing chemistry, manufacturing, and controls, alongside its Knowledge-based In Silico Drug Discovery platform for identifying new therapeutic candidates. Founded in 2001 and previously known as Ensoltek Co., Ltd., Ensol Biosciences is committed to addressing unmet medical needs through its research and development initiatives.

42Maru, Inc. is a South Korean technology company established in 2015, specializing in the development of advanced search engine technology designed for artificial intelligence applications. The firm focuses on creating a deep learning-based question-answering system that accurately interprets user intent and provides precise answers in real-time. Its technology encompasses various domains, including information retrieval, machine reading comprehension, and natural language processing, making it applicable across multiple sectors such as smart speakers, connected cars, chatbots, and home automation devices. 42Maru stands out in the market due to its high accuracy, efficient knowledge base expansion, and low operational costs. The company aims to penetrate the consumer market through strategic B2B2C alliances while supporting multiple languages for global expansion. With a team of experts led by a CEO with over 20 years of industry experience, 42Maru has formed partnerships with major telecommunications companies and financial institutions, positioning itself at the forefront of the emerging AI-driven search paradigm.

Founded in 2017, CURAUM specializes in developing and selling oral care and sleep-related healthcare products. Its key offerings include Clium Cleaner for dental device cleaning, Clium S-Guard for managing obstructive sleep apnea and snoring, and the Clium System for personalized chronic sleeping disorder management.